Compare ALTG & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALTG | ZNTL |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.6M | 156.7M |
| IPO Year | N/A | 2020 |
| Metric | ALTG | ZNTL |
|---|---|---|
| Price | $5.17 | $2.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $11.33 | $5.80 |
| AVG Volume (30 Days) | 200.0K | ★ 578.7K |
| Earning Date | 05-06-2026 | 03-26-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.02 | N/A |
| Revenue Next Year | $3.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.54 | $1.01 |
| 52 Week High | $8.88 | $3.95 |
| Indicator | ALTG | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 33.14 | 41.68 |
| Support Level | $4.57 | $2.10 |
| Resistance Level | $5.84 | $2.69 |
| Average True Range (ATR) | 0.30 | 0.20 |
| MACD | -0.09 | -0.05 |
| Stochastic Oscillator | 10.39 | 9.09 |
Alta Equipment Group Inc is an integrated equipment dealership platform in the U.S. Its segments are Material Handling, Construction Equipment, and Master Distribution. The Material Handling segment is engaged in operations related to the sale, service, and rental of lift trucks in Michigan, Illinois, Indiana, New York, Virginia, and throughout the New England states whereas, the Construction Equipment segment is principally engaged in operations related to the sale, service, and rental of construction equipment in Michigan, Indiana, Illinois, Ohio, Pennsylvania, New York, Florida and throughout the New England States, and The Master Distribution segment is engaged in environmental processing equipment distribution with sub dealers throughout the United States and Canada.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.